Delivery Order SPE2DB20D2014-SPE2DB24FB86C

Award Date 5/9/24
Potential Completion Date 5/10/24
Potential Value $6.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $6,040.77 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of the pharmaceutical product RINVOQ ER 15 MG TABLET UU 30S. This delivery order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp as the prime contractor to provide a comprehensive range of pharmaceutical products and...
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract worth $9,110.83 to Amerisourcebergen Drug Corp's Corporate Office Division on July 1, 2024. The contract is for the supply of RINVOQ ER 15 MG TABLET, a pharmaceutical product, with a performance period through July 2, 2024. This Delivery Order is issued under Amerisourcebergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. Under this IDC,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the delivery of 4,563,982,063 units of RINVOQ ER 30 MG TABLET. The contract has a ceiling value of $6,173.58 and a period of performance through March 18, 2024. This delivery order contract is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of...
The U.S. Department of Defense (DOD) Defense Logistics Agency (DLA) awarded a $14,048.42 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of 4566803438 - RINVOQ ER 15 MG TABLET UU 30S. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a comprehensive vehicle for supplying a range of pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for $18,046.26 to provide RINVOQ ER 30 MG TABLET UU 30S. This order is part of an indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver...
The U.S. Defense Logistics Agency (DLA) awarded a $4,707.34 Firm Fixed Price Delivery Order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on February 10, 2025. The contract, which runs through February 11, 2025, is for the provision of RINVOQ ER 30 MG TABLET UU 30S, a pharmaceutical product. This award is associated with Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $7,074.07 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of RINVOQ ER 30 MG TABLET UU 30S. This order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA Troop Support Medical, with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract has a potential value of $27,175.99 and a completion date of March 1, 2024. Amerisourcebergen Drug Corp is the prime contractor for this delivery order, which is issued under an indefinite delivery contract (IDC) valued at up to $999,999,999.00...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract, valued at $7,275.16, to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of the pharmaceutical product RINVOQ ER 30 MG TABLET UU 30S. The contract has a period of performance through March 12, 2024. Amerisourcebergen Drug Corp is also the prime contractor on a separate $999,999,999.00 indefinite delivery contract (IDC) awarded by DLA, which serves as the...
The Defense Logistics Agency (DLA) has awarded a $8,241.24 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office Division to provide 4564530227 RINVOQ ER 15 MG TABLET UU 30S. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that AmerisourceBergen holds with DLA Troop Support Medical to deliver a comprehensive range of pharmaceutical products and medical supplies to support the Department of Defense (DoD)...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB24FB86C
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to Amerisourcebergen Drug Corp's Corporate Office division. The $6,682.71 contract is for the supply of RINVOQ ER 15 MG TABLET in 30 count units, with a completion date of May 10, 2024. This award is a task order under Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a wide range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not utilize a set-aside designation.

Generated 8/8/24, 10:10 AM